FIELD: biotechnology.
SUBSTANCE: following is proposed: bispecific antibodies capable of binding to blood coagulation factor IX (FIX) and/or its activated form (FIXa) and factor X (FX) and/or its activated form (FXa) and stimulating the activation of FX under the influence of FIXa. Also the following is proposed: an antibody or an antigen-binding fragment thereof that binds to FIX and/or its activated form (FIXa) and is an intermediate in the production of these bispecific antibodies. The invention also relates to a pharmaceutical composition and a kit for the treatment of coagulopathy or bleeding disorders, containing the specified bispecific antibodies.
EFFECT: invention provides improved stimulation of the enzymatic activity of FIXa in relation to FX.
19 cl, 9 dwg, 21 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2019 |
|
RU2747735C2 |
| ANTIBODIES SPECIFIC TO FLT3 AND THEIR APPLICATIONS | 2018 |
|
RU2758513C2 |
| ANTIBODIES SPECIFIC FOR CD70 AND THEIR USE | 2019 |
|
RU2801093C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| ANTIBODY SPECIFICALLY BINDING TO ICAM-1 AND ITS USE | 2019 |
|
RU2789757C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| NEW ANTIBODY COMPOSITIONS FOR CANCER IMMUNOTHERAPY | 2019 |
|
RU2804490C2 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| ILT7 BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2756109C2 |
